UK markets close in 12 minutes

ABIVAX Société Anonyme (0RA9.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
6.05-0.15 (-2.42%)
As of 04:58PM GMT. Market open.
Full screen
Previous close6.20
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Volume4,860
Avg. volumeN/A
Market cap555,412
Beta (5Y monthly)1.23
PE ratio (TTM)N/A
EPS (TTM)-2.47
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Abivax releases the results of its November 9, 2022 ad hoc ordinary and extraordinary general meeting

    EQS-News: ABIVAX / Key word(s): AGM/EGMAbivax releases the results of its November 9, 2022 ad hoc ordinary and extraordinary general meeting 15.11.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.ABIVAX RELEASES THE RESULTS OF ITS NOVEMBER 9, 2022 AD HOC ORDINARY AND EXTRAORDINARY GENERAL MEETING Shareholders approved all proposed resolutionsPARIS, France, November 15, 2022 – 6:00 p.m. (CET) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a phase 3 cl

  • EQS Group

    Abivax: first US patient enrolled in global phase 3 program with obefazimod in ulcerative colitis

    EQS-News: ABIVAX / Key word(s): StudyAbivax: first US patient enrolled in global phase 3 program with obefazimod in ulcerative colitis 11.10.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.ABIVAX: FIRST US PATIENT ENROLLED IN GLOBAL PHASE 3 PROGRAM WITH OBEFAZIMOD IN ULCERATIVE COLITISFirst patient enrolled into the global phase 3 program with obefazimod (“ABTECT-Program”) for the treatment of moderate to severe ulcerative colitis (UC) in the US1,200 UC

  • EQS Group

    ABIVAX ANNOUNCES AD HOC ORDINARY AND EXTRAORDINARY GENERAL MEETING ON NOVEMBER 9, 2022

    EQS-News: ABIVAX / Key word(s): MiscellaneousABIVAX ANNOUNCES AD HOC ORDINARY AND EXTRAORDINARY GENERAL MEETING ON NOVEMBER 9, 2022 03.10.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.ABIVAX ANNOUNCES AD HOC ORDINARY AND EXTRAORDINARY GENERAL MEETING ON NOVEMBER 9, 2022PARIS, FRANCE, October 3, 2022 – 6.00 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284 – ABVX) (the “Company”), a phase 3 clinical-stage biotechnology company harnessing the immune sy